drugset / Trial / NCT04368910

Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria

NCT04368910

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax (P. vivax) malaria

Timeline

Start
2007-09-06
Primary completion
2010-10-16
Completion
2010-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 60 mg Oral
Comparator Chloroquine Small molecule 155 mg Oral
Subject Pyronaridine Unknown 180 mg Oral

Indications